CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024

CorMedix Inc.

2024-Q1 EPS reported -$0.25

Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.
Cash and short-term investments $58.6M; company believes it can fund operations for at least 12 months.
CMS granted HCPCS code and TDAPA for DefenCath effective July 1, 2024, providing 5 years of additional ESRD reimbursement.
Commercial launch of DefenCath in inpatient setting commenced April 15, 2024; outpatient launch expected July 2024.
Entered 5-year supply contract with ARC Dialysis; FDA meeting on DefenCath in TPN requested, feedback expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

CorMedix Inc. reported first quarter ended March 31, 2024 results: net income net loss of $14.5 million, EPS $0.25 per share.

Period: first quarter ended March 31, 2024
Net income: net loss of $14.5 million
EPS: $0.25 per share
Result: reported results

Exact text from the filing

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-041026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.